the ones on the right mean it's time to check in with a clinician
This is the conversation worth having with your physician
The most commonly reported adverse reactions in clinical trials include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and constipation, which occur in a substantial proportion of patients
15,20 Serious GI AEs, though uncommon, have also been reported with GLP-1 RA therapy, including gastroparesis, intestinal obstruction, pancreatitis, and colonic ischemia
But it is unprecedented for drugs to be put on the pathway to widespread adoption in this manner instead of having to go through the more arduous and evidence-based FDA drug approval process, experts say
GLP-1RAs enhance insulin secretion and inhibit glucagon release by the pancreas, resulting in glucose-dependent reductions in plasma glucose